Komaromi Selye Janos Korhaz
- Address
- lock Available on a paid plan
Respiratory Tract Diseases
The pulmonary department at Komaromi Selye Janos Korhaz is conducting research aimed at improving outcomes for patients with Chronic Obstructive Pulmonary Disease (COPD). The studies evaluate the potential of benralizumab to lower the frequency of severe exacerbations in individuals with a history of frequent flare‑ups.
- Biologic therapy impact on COPD exacerbation rates
- Biomarker‑guided patient enrollment strategies
- Long‑term safety and tolerability of new respiratory agents
By focusing on high‑risk COPD populations, the site seeks to reduce hospital admissions and enhance daily functioning for patients living with this chronic lung condition.
Nutritional and Metabolic Diseases
Research in the metabolic health arena explores whether tirzepatide can meaningfully lower morbidity and mortality among adults struggling with obesity and excess weight. The trial compares the investigational agent with placebo to determine its superiority in weight reduction and health risk mitigation.
- Dual GIP/GLP‑1 agonist effectiveness for weight management
- Cardiovascular outcome improvements linked to weight loss
- Integration of metabolic disease treatment into routine care
This work reflects the hospital’s dedication to tackling the growing burden of metabolic disorders and offering innovative therapeutic options to improve patients’ long‑term health.
Site Overview
Activity Indicator
Last 6 months
Trial Flow
How this site's trials are distributed across therapeutic areas and active substances (IMPs), and how they're positioned within their overall lifecycle status. Flow thickness represents the number of unique trials.
Compounds & Molecules Timeline
The time span of clinical-trial activity for the main active substances (IMPs) studied at this site over the last 8 years. Each bar runs from the earliest trial start to the most recent end; a substance with a trial still open has no recorded end and is shown as ongoing.
Sponsor & Partnership
Top sponsors by active trials, and the ones that have come back for more than one study.
Sponsor Network
Top 10 by active trials.
No sponsors linked to active trials.
Partnership History
Sponsors with repeated collaboration (≥ 2 trials).
No repeated partnerships found.
Sponsor Network Graph
How sponsors and therapeutic areas connect across this site's active trials: each link is at least one active trial shared between them, and bigger nodes mean more activity. Click a node to see its exact connections.
Country Benchmark
Compared to 332 other sites in Hungary
Therapeutic Area Benchmark — Hungary
Select a therapeutic area to compare against other sites in Hungary.
Competitor Comparison
Similar sites in the same country running a comparable number of trials (within ±30%), scored on how closely their trial portfolios match this one. Higher percentages mean a more similar profile.
Country: Hungary
Market Share
Country: Hungary
Therapeutic Area Market Share
Select a therapeutic area to view its disease coverage breakdown.
Heat Maps & Advanced Analytics
How often specific conditions appear in trials across this site and comparable sites from the same country. Each row is a site, each column a condition, and each cell the number of trials on it — darker means more activity.
Other Trials in Komaromi Selye Janos Korhaz
lock Showing 1 of 3 trials — the rest is available on a paid plan.
| Trial | Sponsor | Phase | Status | Start Date | End Date |
|---|---|---|---|---|---|
| Effect of Olpasiran on Major Cardiovascular Events in Patients with Atherosclerotic Cardiovascular Disease and Elevated Lipoprotein(a): A Randomized, Placebo-Controlled Study | Amgen Inc. | Phase III | Not Recruiting | May 2023 | — |
IMP list
lock Showing 1 of 2 compounds — the rest is available on a paid plan.
| IMP | Trials | Status | First start | Last start |
|---|---|---|---|---|
| Benralizumab | 1 | Unknown | 2019-11-12 | 2019-11-12 |
Upgrade this site to Business Plan
Own the profile, publish your feasibility data and reach sponsors directly.
Is something out of date?
Tell us what needs correcting and we'll update this profile.
lock Available to Business plan sites only.